The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world safety and efficacy of tarlatamab in patients with small cell lung cancer or extrapulmonary small cell carcinoma.
 
Sanjana Mullangi
No Relationships to Disclose
 
Manidhar Reddy Lekkala
Stock and Other Ownership Interests - Abbvie; crispr therapeutics; Lilly; NeoGenomics Laboratories; Pfizer; Teva
 
Sarah Blocker
No Relationships to Disclose
 
Diana Kim
Employment - University of Kansas Health System
 
Jun Zhang
Consulting or Advisory Role - AstraZeneca; Fosun Pharma; Novocure; Regeneron; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; MJH Life Sciences; Regeneron; Sanofi
Research Funding - Abbvie (Inst); AstraZeneca; BeiGene (Inst); Bridgebio (Inst); Champions Oncology; Genentech/Roche; Hengrui Therapeutics (Inst); Innocare (Inst); Janssen (Inst); KAHR Medical (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics; Mirati Therapeutics (Inst); Nilogen Oncosystems; Novartis (Inst); Takeda
 
Chao Huang
Stock and Other Ownership Interests - Vanguard Funds
Honoraria - Ipsen
Consulting or Advisory Role - Biodesix; Ipsen
Speakers' Bureau - Curio Science; Targeted Oncology
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); EpicentRx; Genentech/Roche (Inst); Henlius (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Regenxbio (Inst)
 
Prakash Neupane
Research Funding - Merck Sharp & Dohme
 
Haoran Li
No Relationships to Disclose
 
Timothy Schieber
No Relationships to Disclose